VANDA PHARMACEUTICALS INC

Vanda Pharma’s FDA rare pediatric designation for VCA‑894A offers new hope for Charcot‑Marie‑Tooth type 2S patients, positioning the biotech firm for breakthrough CNS therapy.

Vanda Pharmaceuticals’ first new motion‑sickness drug, NEREUS™, offers a 67% discount at $85 per dose and could reshape the market after 40+ years of stagnation.

Vanda Pharmaceuticals faces a tough road: negative earnings, a steep stock drop, and a -1.96 P/E ratio, yet its CNS‑focused drugs keep investors on edge for breakthrough therapies.

Vanda Pharmaceuticals urges FDA to withdraw FY 2027 review‑timeline extension, fearing delays to its CNS drug pipeline and investor confidence.

Vanda Pharmaceuticals launches Thetis trial for tradipitant, a small‑molecule anti‑emetic, and challenges FDA’s proposed review‑time extension, aiming to speed GLP‑1 therapy access.

Vanda Pharmaceuticals’ FDA approval of BYSANTI (milsaperidone) for bipolar I and schizophrenia marks a strategic breakthrough, promising a strong exclusivity window, premium pricing, and significant investor upside.

Vanda Pharmaceuticals’ Q4 2025 earnings plunge to –$2.39 EPS, modest 7.6% revenue rise, and FY26 outlook below expectations—investors weigh pipeline promise against widening losses and cash‑burn risks.

Vanda Pharmaceuticals faces legal scrutiny and a negative P/E ratio amid volatile stock; investors weigh risks and future prospects in biotech.

Vanda Pharmaceuticals faces hedge‑fund divestment, fraud claims, and a legal probe while still pitching at JPMorgan Healthcare, testing investor confidence and stock stability.

FDA rejects Vanda’s HETLIOZ® jet‑lag application, citing insufficient real‑world evidence, but the company remains poised to address concerns and seek approval.